The Trump administration has made important progress in loosening the federal government’s grip on private health insurance, freeing up more options for affordable health insurance. But the administration has veered off this free-market track with its  recent proposal to, among other things, slap a form of imported price controls on a specific class of prescription drugs in Medicare.